Thrombophilic mutations in high-risk atrial fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism

Summary

Atrial fibrillation (AF) is a common arrhythmia that results in a high risk of cerebral and peripheral embolism. Factor V Leiden and factor II G20210A variant are two leading conditions for venous thrombosis. The aim of our study was to find out whether these two common prothrombotic mutations play a role in the occurrence of embolic events in AF patients. We investigated 336 non-valvular AF patients and 336 healthy control subjects. Factor II G20210A variant was found in 24/336 patients (7.14%) and in 11/336 of control subjects (3.3%). At a multivariate analysis, factor II G20210A variant was independently associated to AF (OR 2.4 95% CI 1.1-5.2; p<0.05). No significant difference was observed in the prevalence of factor V Leiden in the two groups investigated [6/304 (2.0%) in patients vs 13/336 (3.9%) in controls (p=0.24)]. AF patients were separately analyzed in relation to the occurrence or absence of a cerebral or peripheral embolic event (200 with and 136 without embolic event). The prevalence of the two mutations among AF patients with and without an embolic event was similar [factor II G20210A polymorphism (7% and 7.3% respectively) and factor V Leiden (1.2% and 2.9%, respectively)]. No differences were found in relation to the type of embolic event. Our results suggest a possible relationship between the presence of prothrombin gene variant and AF per se.

Keywords

Atrial fibrillation - stroke - prothrombin gene - factor V Leiden

• References

• 1 Albers G, Dalen J, Laupacis A. et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206S.
• 2 Stroke Prevention in Atrial Fibrillation Committee on Echocardiography. Trans-esophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Intern Med 1998; 128: 639-47.
• 3 Kumagai K, Fukunami M, Ohmori M. et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16: 377-80.
• 4 Lip GYH, Lowe GDO, Rumley A. et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin therapy. Br Heart J 1995; 73: 527-33.
• 5 Hart RG, Benavente O, McBride R. et al. Antithrombotic therapy to prevent stroke in patients with Atrial Fibrillation: a meta-analysis. Ann Intern Med 1999; 157: 1237-40.
• 6 Svensson PJ, Dalhback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 7 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untraslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous trhombosis. Blood 1996; 88: 3698-703.
• 8 Kotler MN, Mintz GS, Segal BL. et al. Clinical uses of two dimensional echocardiography. Am J Cardiol 1980; 45: 1061-82.
• 9 Camerota AJ, Crannley JJ, Hayden WG. Ultrasound imaging for carotid occlusive disease. In: Bernstein EF, ed. Noninvasive Diagnosis. Mosby: St Louis, MO; 1985: 384-95.
• 10 Feinberg WM, Pearce LA, Hart RG. et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 partecipants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke 1999; 30: 2547-53.
• 11 Redondo M, Watzke HH, Stucki B. et al. Coagulation factors II, V, VII, and X, pro-thrombin gene 20210G A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
• 12 Gardemann A, Arsic T, Katz N. et al. The factor II G20210A and factor V G1691A gene transition and coronary heart disease. Thromb Haemost 1999; 81: 208-13.
• 13 Eikelboom JW, Baker I R, Parson R. et al. No association between the 20210G/A pro-thrombin gene mutation: premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
• 14 Russo G, Girelli D, Olivieri O. et al. G20210A prothrombin gene polymorphism and prothrombin activity subjects with or without angiographically documented coronary artery disease. Circulation 2001; 103: 2436-40.
• 15 Rosendaal FR, Siscovick DS, Schwartz SM. et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
• 16 De Stefano V, Chiusolo P, Paciaroni K. et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
• 17 Pengo V, Filippi B, Biasiolo A. et al. Association of the G20210A mutation in the factor II gene with systemic embolism in non-valvular atrial fibrillation. Am J Cardiol 2002; 90: 545-7.
• 18 Lane DA, Grant PJ. Role of haemostatic gene polymorphisms in venous and arterial thrombotic diseases. Blood 2000; 95: 1517-32.
• 19 Wolf PA, Robert RD, Kannel WB. Atrial Fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-88.
• 20 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
• 21 Lin HJ, Wolf P, Kelly-Hayes M. et al. Stroke severity in Atrial Fibrillation The Framing-ham Study. Stroke 1996; 27: 1760-4.
• 22 Stroke prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
• 23 Lip GYH, Lowe GDO. ABC of atrial fibrillation: antithrombotic treatment for atrial fibrillation. BMJ 1996; 312: 45-9.
• 24 Chen Y, Xu S, Bendahhou S. et al. KCNQ1 gain–of-function mutation in familial atrial fibrillation. Science 2003; 299: 251-4.